抗CD19嵌合抗原受体T细胞疗法成功治疗HIV感染的难治性高级别B细胞淋巴瘤患者。 - Suppr

Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma.

作者信息

Abramson Jeremy S, Irwin Kelly E, Frigault Matthew J, Dietrich Jorg, McGree Brianne, Jordan Justin T, Yee Andrew J, Chen Yi-Bin, Raje Noopur S, Barnes Jeffrey A, Davis Benjamin

机构信息

Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.

Division of Psychiatric Oncology, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts.

出版信息

Cancer. 2019 Nov 1;125(21):3692-3698. doi: 10.1002/cncr.32411. Epub 2019 Sep 10.

DOI:10.1002/cncr.32411

PMID:31503324

Abstract

摘要

相似文献

Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma.

Cancer. 2019 Nov 1;125(21):3692-3698. doi: 10.1002/cncr.32411. Epub 2019 Sep 10.

Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.

Clin Cancer Res. 2019 Dec 1;25(23):6995-7003. doi: 10.1158/1078-0432.CCR-19-0101. Epub 2019 Aug 23.

The promise of CAR T-cell therapy in aggressive B-cell lymphoma.

Best Pract Res Clin Haematol. 2018 Sep;31(3):293-298. doi: 10.1016/j.beha.2018.07.011. Epub 2018 Aug 1.

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.

J Vis Exp. 2018 Oct 16(140):58492. doi: 10.3791/58492.

Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.

Drugs Today (Barc). 2018 Mar;54(3):187-198. doi: 10.1358/dot.2018.54.3.2776625.

Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma.

Leukemia. 2021 Dec;35(12):3581-3584. doi: 10.1038/s41375-021-01324-z. Epub 2021 Jun 18.

CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.

Hum Gene Ther. 2017 Dec;28(12):1147-1157. doi: 10.1089/hum.2017.126.

Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss.

Am J Hematol. 2019 Oct;94(10):E273-E275. doi: 10.1002/ajh.25591. Epub 2019 Aug 13.

Clinical immunotherapy of B-cell malignancy using CD19-targeted CAR T-cells.

Curr Gene Ther. 2014 Feb;14(1):35-43. doi: 10.2174/1566523213666131223130554.

The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.

Ann Hematol. 2018 Aug;97(8):1327-1335. doi: 10.1007/s00277-018-3368-8. Epub 2018 May 15.

引用本文的文献

Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies.

J Hematol Oncol. 2025 Jul 1;18(1):68. doi: 10.1186/s13045-025-01702-5.

Increased and persistent absolute CD4+ T cell count in an HIV-associated Burkitt lymphoma patient with central nervous system involvement after axicabtagene ciloleucel therapy.

Cancer Biol Med. 2025 Jun 27;22(6):644-7. doi: 10.20892/j.issn.2095-3941.2025.0087.

Autologous HIV-specific T cell therapy targeting conserved epitopes is well-tolerated in six adults with HIV: an open-label, single-arm phase 1 study.

Nat Commun. 2025 May 15;16(1):4510. doi: 10.1038/s41467-025-59810-2.

Immune reconstitution and evolution of B-cell-stimulating cytokines after R-CHOP therapy for HIV-associated DLBCL.

Blood Adv. 2024 Dec 10;8(23):6017-6027. doi: 10.1182/bloodadvances.2024014116.

Human immunodeficiency virus-associated Lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Hemasphere. 2024 Sep 3;8(9):e150. doi: 10.1002/hem3.150. eCollection 2024 Sep.

Cancer in People with HIV.

Infect Dis Clin North Am. 2024 Sep;38(3):531-557. doi: 10.1016/j.idc.2024.06.007.

Overview of infectious complications among CAR T- cell therapy recipients.

Front Oncol. 2024 Jul 3;14:1398078. doi: 10.3389/fonc.2024.1398078. eCollection 2024.

Simultaneous targeting of B-cell malignancies and human immunodeficiency virus with bispecific chimeric antigen receptor T cells.

Haematologica. 2024 Sep 1;109(9):3053-3058. doi: 10.3324/haematol.2024.285321.

CD20 CAR T cells safely and reversibly ablate B cell follicles in a non-human primate model of HIV persistence.

Mol Ther. 2024 May 1;32(5):1238-1251. doi: 10.1016/j.ymthe.2024.02.030. Epub 2024 Feb 27.

Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management.

Curr Oncol. 2023 Jul 1;30(7):6330-6352. doi: 10.3390/curroncol30070467.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献